What's New

Dec.07.2016……Opdivo (nivolumab) Alone or Combined With Yervoy (ipilimumab) Shows Encouraging Response and Survival Rates in Recurrent Small Cell Lung Cancer, From Phase 1/2 Study CheckMate -032

Dec.02.2016……OPDIVO® (nivolumab) Intravenous Injection Receives Approval for Supplemental Indication of Relapsed or Refractory Classical Hodgkin Lymphoma in Japan

Nov.29.2016……European Commission Approves Bristol-Myers Squibb's Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin

Nov.18.2016……Phase 1/2 Data Combining Urelumab with Opdivo (nivolumab) in Hematologic and Solid Tumors Suggest Increased Antitumor Effect in Patients with Melanoma

Nov.18.2016……ONO Announces Results from Phase 1/2 and Long-term Clinical Studies of “Etelcalcetide Hydrochloride (ONO-5163)” in Hemodialysis Patients with Secondary Hyperparathyroidism in Japan at ASN Kidney Week 2016

Nov.15.2016……Opdivo (nivolumab) and Yervoy (ipilimumab) Regimen Shows Promising Efficacy and Safety in Previously Treated Patients With Advanced Form of Bladder Cancer

Nov.14.2016……Bristol-Myers Squibb's Opdivo® (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer

Nov.14.2016……Amgen Receives Marketing Authorization Approval from European Commission for Parsabiv™ (Etelcalcetide) to Treat Patients with Secondary Hyperparathyroidism

Nov.10.2016……Opdivo® (nivolumab) Intravenous Infusion Demonstrates a Significant Extension in Overall Survival Versus Placebo in Patients with Unresectable Advanced or Recurrent Gastric Cancer Refractory to or Intolerant of Standard Therapy in Phase III Clinical Study (ONO-4538-12 Study)

Nov.07.2016……Announcement on Financial Results for FY2016 2Q

Oct.26.2016……New Results Presented for Opdivo (nivolumab) Demonstrated Encouraging Response Rate in an Expanded Population of Heavily Pre-Treated Classical Hodgkin Lymphoma Patients

Oct.26.2016……U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Patients With Advanced Form of Bladder Cancer

Oct.24.2016……Filing of Patent Infringement Lawsuit against MSD K.K.

Oct.18.2016……Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin

Oct.11.2016……Opdivo (nivolumab) Shows Durable Response in Longest Follow-up for a PD-1 Inhibitor in Previously Treated Advanced Non-Small Cell Lung Cancer

Oct.11.2016……Updated Results Presented for the Opdivo (nivolumab) and Yervoy (ipilimumab) Combination in Metastatic Renal Cell Carcinoma From Phase 1 Study

Oct.11.2016……Bristol-Myers Squibb Presents Results From CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) Monotherapy Versus Chemotherapy as First-Line Therapy in a Broad PD-L1 Positive Population With Advanced Lung Cancer

Oct.11.2016……Opdivo (nivolumab) Stabilized Patient-reported Outcomes in Patients With Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck in Pivotal Phase 3 CheckMate -141 Study

Oct.11.2016……Results From CheckMate-275 Validate Further Study of Opdivo (nivolumab) in Patients With Advanced Form of Bladder Cancer

Sep.28.2016……Amgen Announces Top-line Results from Phase III Kyprolis® (Carfilzomib) CLARION Study in Newly Diagnosed Multiple Myeloma Patients

Sep.21.2016……European Medicines Agency Validates Bristol-Myers Squibb's Type II Variation Application for Opdivo (nivolumab) in Advanced Form of Bladder Cancer

Sep.14.2016……European Commission Approves Bristol-Myers Squibb's ORENCIA® (abatacept) for the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis Not Previously Treated with Methotrexate

Sep.07.2016……ONO Receives Approval for OPDIVO® (nivolumab) Intravenous Infusion for Treatment of Unresectable or Metastatic Renal Cell Carcinoma in Japan as Part of Partial Change in Approved Items of Manufacturing and Marketing Authorization

Sep.07.2016……ONO Launches KYPROLIS® for Intravenous Injection 10 mg and 40 mg Proteasome Inhibitor

Sep.07.2016……ONO Submits Supplemental New Drug Application in Japan for “KYPROLIS® for Intravenous Injection 10 mg and 40 mg", a Proteasome Inhibitor, for Relapsed or Refractory Multiple Myeloma

Sep.05.2016……Announcement on posting of Corporate Report 2016

Aug.09.2016……Influence of Cliical Results from CheckMate-026, a Phase III Study of Opdivo® (nivolumab) in Treatment-Naïve Patients with Advanced Non-Small Cell Lung Cancer

Aug.08.2016……Bristol-Myers Squibb Announces Top-Line Results from CheckMate-026, a Phase 3 Study of Opdivo (nivolumab) in Treatment-Naïve Patients with Advanced Non-Small Cell Lung Cancer

Aug.02.2016……Announcement on Financial Results for FY2016 1Q

Jul.27.2016……ONO Submits Supplemental Application of OPDIVO® (Nivolumab) for Recurrent or Metastatic Head and Neck Cancer for a Partial Change in Approved Items of Manufacturing and Marketing Approval in Japan

Jul.19.2016……Bristol-Myers Squibb Announces Regulatory Updates for Opdivo (nivolumab) in Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Jul.14.2016……Notice Concerning Determination of Details of Issuance of Stock Options (Stock Acquisition Rights)

Jul.12.2016……Amgen Receives Approval for Kyprolis® (Carfilzomib) For Expanded Indication for the Treatment of Relapsed Multiple Myeloma

Jul.11.2016……ONO enters into license agreement with Celyad for its allogeneic CAR T-cell therapy (NKR-2)

Jul.06.2016……European Commission approves ONGENTYS® (opicapone) a novel treatment for Parkinson's disease patients with motor fluctuations

Jul.04.2016……ONO Receives Manufacturing and Marketing Approval in Japan for KYPROLIS® (INN: Carfilzomib; development code: ONO-7057), a Proteasome Inhibitor, in Relapsed or Refractory Multiple Myeloma

Jun.29.2016……Notice of Resolutions Passed at The 68th Ordinary General Shareholders' Meeting

Jun.29.2016……Notice Concerning Issuance of Stock Options (Stock Acquisition Rights)

Jun.28.2016……Opdivo® (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Advanced Form of Bladder Cancer

Jun.15.2016……New Data on Opdivo (nivolumab) Indicate Benefit in Heavily Pre-Treated Classical Hodgkin Lymphoma Patients in Phase 2, Single-Arm Pivotal Trial

Jun.09.2016……First Presentation of Phase 2 CheckMate-142 Study Evaluating Opdivo® (nivolumab) Alone or in Combination with Yervoy® (ipilimumab) Demonstrates Encouraging Clinical Activity in MSI-High Metastatic Colorectal Cancer

Jun.08.2016……Opdivo® (nivolumab) and Yervoy® (ipilimumab) Combination Regimen Shows Clinically Meaningful Responses in First-Line Advanced Non-Small Cell Lung Cancer In Updated Phase 1b CheckMate -012

Jun.07.2016……Long-Term Data from Two Trials Evaluating the Opdivo® (nivolumab) and Yervoy® (ipilimumab) Regimen in Advanced Melanoma Continues to Validate Bristol-Myers Squibb's Immuno-Oncology Combination Approach

Jun.06.2016……Long-Term Survival and Improvement in Quality of Life Observed with Opdivo® (nivolumab) in Advanced Renal Cell Carcinoma Patients Based on New Data Presented at the 2016 ASCO Annual Meeting

Jun.06.2016……Promising Response Rates with Opdivo® (nivolumab) Observed In Advanced Form of Bladder Cancer From Phase 1/2 Study CheckMate-032

Jun.03.2016……Amgen Receives Positive CHMP Opinion to Extend Indication of Kyprolis® (Carfilzomib) for the Treatment of Relapsed Multiple Myeloma

Jun.01.2016……Notice to Convene the 68th Ordinary General Shareholders' Meeting

May.25.2016……Launch of Orencia® SC 125 mg Auto-injector 1 mL for Treatment of Rheumatoid Arthritis

May.24.2016……Two-Year Overall Survival Data from Two Pivotal Opdivo® (nivolumab) Trials Demonstrate Sustained Benefit In Patients with Advanced Non-Small Cell Lung Cancer

May.24.2016……ONO Announces Results from Phase 1/2 and Phase 3 Clinical Studies of gEtelcalcetide Hydrochloride (ONO-5163)h in Hemodialysis Patients with Secondary Hyperparathyroidism in Japan at ERA-EDTA Congress

May.20.2016……Opdivo® (nivolumab) Granted First Approval of a PD-1 Inhibitor in Hematology for the Treatment of Classical Hodgkin Lymphoma Patients Who Have Relapsed or Progressed After Auto-HSCT and Post-transplantation Brentuximab Vedotin by the FDA

May.20.2016……European Commission Approves the First and Only Immuno-Oncology Combination, Opdivo® (nivolumab) + Yervoy® (ipilimumab) Regimen, for Treatment of Advanced Melanoma

May.17.2016……ONO Enters an Agreement with IDAC Theranostics relating to Exclusive Evaluation and License Negotiation on IT1208, anti-CD4 antibody

May.11.2016……Announcement on Financial Results for FY2015

May.09.2016……ONO PHARMA TAIWAN Receives Approval of OPDIVO® (Nivolumab) for New Drug Application for Unresectable or Metastatic Melanoma and Metastatic Squamous Non-Small Cell Lung Cancer in Taiwan

May.09.2016……Bristol-Myers Squibb's Opdivo® (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

May.06.2016……Revision of Consolidated Financial Forecasts

May.06.2016……Notice regarding Differences between Non-consolidated Results for the Fiscal year Ended March 31, 2016 and those for the Previous Fiscal Year

Apr.28.2016……Announcement on Candidates of Members of the Board of Directors, Audit & Supervisory Board Members and Corporate Officers

Apr.22.2016……First Presentation of Two-Year Overall Survival Data for Opdivo® (nivolumab) in Combination with Yervoy® (ipilimumab) Showed Superior Efficacy Versus Yervoy Alone in Advanced Melanoma

Apr.21.2016……First Presentation of Overall Survival Data for Opdivo® (nivolumab) Shows Significant Survival Benefit at One-Year Versus Investigator's Choice in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Apr.19.2016……Support for Relief Efforts to the Kumamoto Earthquake

Apr.19.2016……U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb's Supplemental Biologics License Application for Opdivo® (nivolumab) for the Treatment of Classical Hodgkin Lymphoma Patients

Apr.13.2016……European Commission Approves Expanded Use of Opdivo® (nivolumab) to Include Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

Apr.11.2016……ONO Announces Sales Results of OPDIVO® (Nivolumab), Antineoplastic Agent for Fiscal Year 2015 and its Sales Forecasts for Fiscal Year 2016

Apr.08.2016……European Commission Approves Bristol-Myers Squibb's Opdivo® (nivolumab) for Previously Treated Advanced Renal Cell Carcinoma

Apr.06.2016……Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) in Combination with Yervoy® (ipilimumab) for Treatment of Advanced Melanoma

Apr.04.2016……ONO PHARMA KOREA Receives Approval for OPDIVO® (Nivolumab) for Expanded Application of Unresectable or Metastatic Melanoma and Additional Indication of Locally Advanced or Metastatic Non-small Cell Lung Cancer Refractory to Existing Chemotherapy in South Korea

Apr.01.2016……European Medicines Agency Validates Bristol-Myers Squibb's Application for Opdivo® (nivolumab) for the Treatment of Classical Hodgkin Lymphoma Patients

Mar.30.2016……ONO Enters Licensing Agreement with Santen for ONO-9054, FP/EP3 Dual Receptor Agonist

Mar.18.2016……ONO Submits Supplemental Application of OPDIVO® (Nivolumab) for Additional Indication of Relapsed or Refractory Hodgkinfs Lymphoma

Mar.18.2016……ONO Receives Approval for PROEMEND® for Intravenous Infusion 150 mg for Treatment of Chemotherapy-Induced Nausea and Vomiting for a Partial Change in Approved Items for Additional Application to Pediatric Patients

Mar.11.2016……Reconstruction Assistance Activities gOperation Slimmer and Healthierh (SUKOYAKARADA DAISAKUSEN) Held in Miyagi Prefecture - Recreation with the Athletes or Holding a Lifestyle Seminar -

Mar.04.2016……ONO Announces Stock Split and Partial Amendment to the Articles of Incorporation

Mar.02.2016……Bristol-Myers Squibb Receives Two Positive CHMP Opinions for Opdivo® (nivolumab) for Patients with Previously Treated Advanced Non-Squamous Non-Small Cell Lung Cancer and Renal Cell Carcinoma

Mar.01.2016……Completion of the new Research Building (The Third Building) in the Minase Research Institute

Feb.29.2016……ONO Receives Approval for OPDIVO® (Nivolumab) for a Partial Change in Approved Items for Treatment of Unresectable Melanoma in Japan

Feb.26.2016……Manufacturing and Marketing Approval of Orencia®SC 125mg Auto-injector 1mL for Rheumatoid Arthritis Treatment

Feb.12.2016……Support for Relief Efforts to Southern Taiwan Earthquake

Feb.02.2016……CheckMate -141, a Pivotal Phase 3 Opdivo (nivolumab) Head and Neck Cancer Trial, Stopped Early

Feb.02.2016……Announcement on Financial Results for FY2015 3Q

Feb.02.2016……Revision of Consolidated Financial Forecasts

Jan.28.2016……Bristol-Myers Squibb's Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status

Jan.22.2016……FDA Approves NEW Kyprolis® (Carfilzomib) COMBINATION THERAPY for the treatment of patients with Relapsed Or Refractory multiple myeloma

Jan.14.2016……ONO Submits Manufacturing and Marketing Approval Application in Japan for “Etelcalcetide Hydrochloride” (ONO-5163), a Calcimimetic Agent, for Secondary Hyperparathyroidism in Patients on Hemodialysis

Dec.18.2015……Initiating AVERT-2 Study in Japan, an International Phase IIIb Clinical Study of Orencia in Previously Untreated Rheumatoid Arthritis Patients

Dec.17.2015……ONO receives manufacturing and marketing approval partial amendment approval for OPDIVO® (generic name: nivolumab) for treatment of patients with unresectable, advanced or recurrent non-small cell lung cancer in Japan

Dec.11.2015……ONO submits manufacturing and marketing approval partial amendment application for OPDIVO® (generic name: nivolumab) for treatment of patients with unresectable or metastatic renal cell carcinoma in Japan

Dec.09.2015……Amgen Submits Application In Europe To Expand Indication Of Kyprolis® (carfilzomib) For The Treatment Of Relapsed Multiple Myeloma

Dec.02.2015……Bristol-Myers Squibb Announces Regulatory Update for Opdivo (nivolumab) in Advanced Melanoma

Dec.01.2015……HELSINN ANNOUNCES EUROPEAN MEDICINES AGENCY ACCEPTANCE OF MARKETING AUTHORIZATION APPLICATION FOR ANAMORELIN HCL

Nov.30.2015……Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma

Nov.25.2015……Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab), the Only Treatment to Deliver Significant Overall Survival in Advanced Renal Cell Carcinoma vs. a Standard of Care, in Patients Who Have Received Prior Anti-Angiogenic Therapy

Nov.25.2015……New Long-Term Data on Opdivo and the Opdivo + Yervoy Regimen Shows Survival Benefit Across Lines of Therapy in Advanced Melanoma

Nov.24.2015……European Commission Approves Kyprolis® (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple Myeloma

Nov.17.2015……U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Advanced Renal Cell Carcinoma

Nov.06.2015……European Medicines Agency Validates Bristol-Myers Squibbfs Type II Variation Application for Opdivo (nivolumab) in Previously Treated Advanced Renal Cell Carcinoma

Nov.04.2015……Announcement on Financial Results for FY2015 2Q

Oct.30.2015……Bristol-Myers Squibb's Opdivo (nivolumab) Recipient of Prix Galien USA 2015 Award for Best Biotechnology Product

Oct.26.2015……Revisions of Consolidated Financial Forecasts

Oct.14.2015……Bristol-Myers Squibb's Opdivo (nivolumab) Receives Expanded FDA Approval in Previously-Treated Metastatic Non-Small Cell Lung Cancer (NSCLC), Offering Improved Survival to More Patients

Oct.05.2015……Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for the Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma

Sep.30.2015……Opdivo (nivolumab) Demonstrates Long Term Survival Benefit in Patients with Previously Treated Non-Squamous Non-Small Cell Lung Cancer in CheckMate -057

Sep.29.2015……Bristol-Myers Squibb Announces U.S. Food and Drug Administration Regulatory Filing Update for the Opdivo+Yervoy Regimen in Patients with Previously Untreated Advanced Melanoma

Sep.28.2015……Opdivo (nivolumab) Demonstrates Superior Overall Survival in a Phase 3 Trial Compared to Standard of Care in Patients with Previously Treated Advanced Renal Cell Carcinoma

Sep.24.2015……FDA GRANTS PRIORITY REVIEW FOR AMGEN'S SUPPLEMENTAL NEW DRUG APPLICATION FOR EXPANDED LABELING OF KYPROLIS® (CARFILZOMIB) IN RELAPSED MULTIPLE MYELOMA

Sep.17.2015……Bristol-Myers Squibb's Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Advanced Renal Cell Carcinoma

Sep.17.2015……ONO Received Two Prizes in gAward of Companies Promoting Gender Equality and Work-Family Balance 2015h Hosted by the Ministry of Health, Labour and Welfare

Sep.11.2015……New Cohorts from CheckMate -012 Assess Optimal Dosing of Opdivo+Yervoy in the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer

Sep.11.2015……Follow-up Data from Two Pivotal Opdivo (nivolumab) Trials Demonstrates Sustained Survival Results in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

Sep.07.2015……AMGEN SUBMITS MARKETING AUTHORIZATION APPLICATION FOR NOVEL INTRAVENOUS CALCIMIMETIC ETELCALCETIDE (AMG 416) TO THE EUROPEAN MEDICINES AGENCY

Sep.03.2015……U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Non-Squamous Non-Small Cell Lung Cancer Patients

Aug.26.2015……ONO Submits Manufacturing and Marketing Approval Application in Japan for gCarfilzomib (ONO-7057)h, a Proteasome Inhibitor, in Relapsed or Refractory Multiple Myeloma

Aug.26.2015……AMGEN SUBMITS APPLICATION IN THE US FOR ETELCALCETIDE (AMG 416) FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM

Aug.24.2015……ONO obtained approval for additional "dosage and administration" of RIVASTACH® PATCH for the treatment of Alzheimer-Type Dementia -Introduction of a one-step titration that enables more rapid administration of effective dosage-

Aug.18.2015……U.S. Food and Drug Administration Extends Action Date for Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Untreated Advanced Melanoma

Aug.04.2015……Announcement on Financial Results for FY2015 1Q

July.31.2015……ONO submits manufacturing approval partial amendment application for OPDIVO® (generic name: Nivolumab) for treatment of patients with unresectable melanoma in Japan

July.28.2015……European Medicines Agency Validates Two Parallel Type II Variation Applications to Extend the Opdivo (nivolumab) Indication in Europe

July.27.2015……FDA Approves Kyprolis® (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple Myeloma

July.22.2015……European Commission Approves Nivolumab BMS, the First PD-1 Immune Checkpoint Inhibitor in Europe Proven to Extend Survival for Patients with Previously-Treated Advanced Squamous Non-Small Cell Lung Cancer

July.22.2015……CheckMate-025 (global clinical trial), a Pivotal Phase III Opdivo (nivolumab) Renal Cancer Trial Stopped Early

July.21.2015……ONO submits additional indication application for OPDIVO® (generic name: Nivolumab) for the treatment of patients with unresectable, advanced or recurrent non-small cell lung cancer

July.13.2015……Notice Concerning Determination of Details of Issuance of Stock Options (Stock Acquisition Rights)

Jun.26.2015……Notice Concerning Issuance of Stock Options (Stock Acquisition Rights)

Jun.22.2015……European Commission Approves Bristol-Myers Squibb's Opdivo (nivolumab), the First and Only PD-1 Checkpoint Inhibitor Approved in Europe, for Both First-Line and Previously-Treated Advanced Melanoma Patients

Jun.12.2015……New Post Hoc Analyses of Phase 3b Data Examine Treatment with Orencia® (abatacept) Plus Methotrexate (MTX) in Patients with Early Moderate to Severe Rheumatoid Arthritis (RA) and Markers of Poor Prognosis

Jun.10.2015……TECOS, the Trial Evaluating Cardiovascular Outcomes with JANUVIA® (Sitagliptin), Met Primary Endpoint in Patients with Type 2 Diabetes

Jun.05.2015……U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo+Yervoy Regimen in Patients with Previously Untreated Advanced Melanoma

Jun.05.2015……Phase III CheckMate-067 Trial Demonstrates Superior Progression-Free Survival of Opdivo+Yervoy Regimenor Opdivo Monotherapyvs. Yervoy Monotherapy in Previously Untreated Patients with Advanced Melanoma

Jun.03.2015……Opdivo (nivolumab) First PD-1 Inhibitor to Demonstrate Superior Overall Survival Versus Standard of Care (docetaxel) in Previously-Treated Non-Squamous Non-Small Cell Lung Cancer in Pivotal Phase III Trial

Jun.02.2015……Opdivo (nivolumab) Demonstrates Superior Survival Compared to Standard of Care (docetaxel) for Previously-Treated Squamous Non-Small Cell Lung Cancer in Phase III Trial

Jun.02.2015……Phase I/II Opdivo (nivolumab) Trial Shows Bristol-Myers Squibbfs PD-1 Immune Checkpoint Inhibitor is First to Demonstrate Anti-Tumor Activity In Patients With Hepatocellular Carcinoma

Jun.01.2015……Notice to Convene the 67th Ordinary General Shareholders' Meeting

May.27.2015……ONO Submits Additional Indication Application for gPROEMEND® for Intravenous Infusion 150mgh for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients Aged 6 Months and Older

May.26.2015……Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Nivolumab (Opdivo, Nivolumab BMS) for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer in Previously-Treated Patients

May.12.2015……Announcement on Financial Results for FY2014

May.12.2015……Position and Policies Concerning the Reduction of the Minimum Investment Unit

May.12.2015……Notice Concerning Issuance of Stock Options (Stock Acquisition Rights)

Apr.30.2015……Bristol-Myers Squibb Company announced about Opdivo (nivolumab).

Apr.27.2015……Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Opdivo (nivolumab) for the Treatment of Advanced Melanoma in Both First-Line and Previously Treated Patients

Apr.22.2015……ONO submits additional indication application for OPDIVO® (generic name: Nivolumab) for the treatment of patients with unresectable, advanced or recurrent non-small cell lung cancer (except non-squamous cell carcinoma)

Apr.22.2015……First Randomized Study Evaluating Opdivo (nivolumab)+Yervoy (ipilimumab) Regimen Demonstrates Superior Efficacy Versus Yervoy Alone in Patients with Previously Untreated Advanced Melanoma

Apr.21.2015……CheckMate -057, a Pivotal III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early

Apr.20.2015……(Warning) Be cautious about SNS sites under the name of eONO PHARMACEUTICAL CO., LTD.f

Apr.06.2015……Announcement on Candidates of Members of the Board of Directors, Corporate Auditors and Corporate Officers

Mar.27.2015……Reconstruction Assistance ActivitiesgOperation Slimmer and Healthierh (SUKOYAKARADA DAISAKUSEN) Start from Fukushima Prefecture Exercise Measurement and Recreation with the athletes or Holding a Lifestyle Seminar

Mar.26.2015……ONO Holds The Visiting Lecture about Alzheimer's disease for Junior high school and Senior high school Students

Mar.23.2015……ONO Receives the Approval of the New Drug Application (NDA) for Human Anti-human PD-1 Monoclonal Antibody gOPDIVO®h for the Treatment of Melanoma in South Korea

Mar.19.2015……Opicapone significantly improves OFF-time in fluctuating Parkinson's Disease patients as add-on to levodopa

Mar.16.2015……ONO and CCPC enter into an agreement on development and commercialization of Limaprost in Taiwan

Mar.05.2015……FDA Approves Opdivo (nivolumab) for the Treatment of Patients with Previously Treated Metastatic Squamous Non-Small Cell Lung Cancer

Mar.03.2015……U.S. Food and Drug Administration Accepts Biologics Licensing Application for Opdivo (nivolumab) for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer

Mar.02.2015……HEAD-TO-HEAD PHASE 3 TRIAL OF KYPROLIS® (CARFILZOMIB) VERSUS VELCADE® (BORTEZOMIB) MET PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL

Feb.16.2015……ONO PHARMACEUTICAL CO., LTD. , and Dako, an Agilent Technologies company announce collaboration on development of PD-L1 companion diagnostic test for investigational cancer drug Opdivo® (nivolumab)

Feb.03.2015……Announcement on Financial Results for FY2014 3Q

Jan.29.2015……AMGEN SUBMITS APPLICATIONS IN THE US AND EUROPE FOR KYPROLIS® (CARFILZOMIB) FOR THE TREATMENT OF RELAPSED MULTIPLE MYELOMA

Jan.15.2015……CheckMate -017, A Phase 3 Study of Opdivo (Nivolumab) Compared to Docetaxel in Patients with Second-Line Squamous Cell Non-small Cell Lung Cancer, Stopped Early

Jan.15.2015……Outsourcing of Logistics Operation

Dec.26.2014……Bristol-Myers Squibb Receives Accelerated Approval of Opdivo (nivolumab) from the U.S. Food and Drug Administration

Dec.19.2014……ONO AND GILEAD ANNOUNCE EXCLUSIVE LICENSE AGREEMENT TO DEVELOP BTK INHIBITOR, ONO-4059, FOR THE TREATMENT OF B-CELL MALIGNANCIES AND OTHER DISEASES

Dec.11.2014……ONO Establishes a Local Subsidiary in Taiwan

Dec.10.2014……ONO PHARMACEUTICAL, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo (nivolumab) and Mogamulizumab in Advanced Solid Tumors

Dec.10.2014……Opdivo (nivolumab) Demonstrates High Overall Response Rate of 87% for Treatment of Relapsed or Refractory Hodgkin Lymphoma

Nov.19.2014……Study Comparing Opdivo (nivolumab) to Chemotherapy in Treatment Naive Advanced Melanoma Patients Marks First PD-1 Immune Checkpoint Inhibitor to Demonstrate a Survival Benefit in a Phase 3 Trial

Nov.05.2014……ONO files an application for RIVASTACH® PATCH for adding dosage and administration in Japan

Nov.05.2014……Announcement on Financial Results for FY2014 2Q

Oct.31.2014……Phase 2 Objective Response Rates and Survival Data for Opdivo (nivolumab) in Heavily Pre-treated Advanced Squamous Cell Non-Small Cell Lung Cancer to be Presented at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology

Oct.31.2014……Helsinn Group, Switzerland, announced new data on Fatigue from Phase III Trial (ROMANA 1) of Anamorelin/ONO-7643 in patients with Cancer Anorexia-Cachexia Syndrome (CACS) associated with Non-Small Cell Lung Cancer at 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology

Oct.29.2014……Establishment of GPCR Consortium, a New International Partnership, to Advance Structural Information about G-protein Coupled Receptors

Oct.08.2014……Revisions of Consolidated Financial Forecasts

Oct.07.2014……Approval for the Stability-Improved Formulation of Limaprost, an Oral Prostaglandin E1 Analogue in Japan

Oct.03.2014……European Medicines Agency Validates the Marketing Authorization Application for Opdivo (Nivolumab) in Non-Small Cell Lung Cancer

Oct.02.2014……Bristol-Myers Squibb Announces Multiple Regulatory Milestones for Opdivo (nivolumab) in the U.S. and European Union

Sep.30.2014……Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy® (ipilimumab) Presented at the ESMO 2014 Congress

Sep.29.2014……Helsinn Group, Switzerland, announced the results of Phase III Trials (ROMANA 1 and ROMANA 2) of Anamorelin/ONO-7643 in patients with Cancer Anorexia-Cachexia Syndrome (CACS) associated with Non-Small Cell Lung Cancer

Sep.02.2014……Human Anti-human PD-1 Monoclonal Antibody OPDIVO® Intravenous Infusion 20 mg/100 mg launches in Japan for Treatment of Unresectable Melanoma

Aug.20.2014……Announcement of top-line results from Phase 3 FOCUS Trial of Carfilzomib (ONO-7057), a proteasome inhibitor, in patients with relapsed and advanced refractory multiple myeloma

Aug.11.2014……Phase 3 ASPIRE Trial of Carfilzomib (ONO-7057), a proteasome inhibitor, in patients with relapsed multiple myeloma met primary endpoint (Progression-free survival)

Aug.04.2014……Announcement on Financial Results for FY2014 1Q

July.28.2014……Ono and Meiji Seika Pharma enter into an agreement on development and ommercialization of Limaprost in Thailand and Indonesia

July.24.2014……ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan

July.11.2014……Human Anti-human PD-1 Monoclonal Antibody OPDIVO® Bristol-Myers Squibb plans for Third Quarter Submission of a Biologics License Application for Previously Treated Advanced Melanoma

July.09.2014……Ono Enters into the Collaboration Agreement with the University of Tokyo regarding Access to Ono's Compound Library

July.04.2014……Human Anti-human PD-1 Monoclonal Antibody "OPDIVO® Intravenous Infusion 20 mg/100 mg" Receives Manufacturing and Marketing Approval in Japan for the Treatment of Unresectable Melanoma

Jun.27.2014……Notice to Resolutions Passed at the 66th Ordinary General Shareholders' Meeting

Jun.25.2014……2014Fully Human Anti-PD-1 Antibody Nivolumab ("ONO-4538/BMS-936558") Demonstrates Superior Overall Survival Compared to Dacarbazine in Phase 3 First-Line Melanoma Study (CheckMate -066)

Jun.17.2014……Termination of the license agreement for ONO-4641 mutually agreed by Ono and Merck

Jun.05.2014……Notice to Convene the 66th Ordinary General Shareholders' Meeting

Jun.03.2014……Fully Human Anti-PD-1 Antibody gONO-4538/BMS-936558hResults from Phase 1 Study in Patients with Melanoma Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO)

May.23.2014……Glactiv® has obtained the approval of the partial change in the indications of "type 2 diabetes"

May.23.2014……FORXIGAR® launches in Japan for the treatment of Type 2 diabetes

May.13.2014……Position and policies concerning the reduction of the minimum investment unit

May.13.2014……Announcement on Candidates of Members of the Board of Directors and Corporate Officers

May.13.2014……Announcement on Financial Results for FY2013

Apr.30.2014……Discontinuation of the license agreement for a new therapeutic agent for thrombocytopenia

Mar.24.2014……FORXIGA® (dapagliflozin) receives regulatory approval in Japan for the treatment of Type 2 diabetes

Mar.06.2014……ONO establishes an innovative research network called "Orientem Innovation" together with Tohoku University & The University of Tokyo

Feb.04.2014……Announcement on Financial Results for FY2013 3Q

Jan.17.2014……Annoucement on CSR Report 2013

Dec.24.2013……ONO Files for Regulatory Approval of "Nivolumab (ONO-4538/BMS-936558)" for Treatment of Malignant Melanoma

Dec.16.2013……FDA Advisory Committee Recommends the Investigational SGLT2 Inhibitor Dapagliflozin for the Treatment of Type 2 Diabetes in Adults

Dec.13.2013……Ono Establishes a Local Subsidiary in South Korea

Dec.09.2013……Clinical Trial Application submitted for Phase I study of ONO-7268MX2, peptide-cocktail vaccine for hepatocellular carcinoma

Dec.03.2013……AstraZeneca and Ono Enter Co-promotion Agreement in Japan for Dapagliflozin

Nov.22.2013……Approval for Additional Indication of Onoact® 50 for injection, Short-Acting Selective β1 Blocker in Japan

Nov.14.2013……Results of Phase II/III Study of ONO-2745/CNS 7056, a Short-acting General Anesthetic

Nov.05.2013……Announcement on Financial Results for FY2013 2Q

Oct.28.2013……Fully Human Anti-PD-1 Antibody "Nivolumab (ONO-4538/BMS-936558)" Updated Results from a Phase 1 Study in Patients with NSCLC Presented at 15th World Conference on Lung Cancer

Oct.22.2013……Ono Enters into License Agreement with Valeant

Oct.09.2013……Ono Establishes a Local Subsidiary in South Korea

Oct.01.2013……Fully Human Anti-PD-1 Antibody "Nivolumab (ONO-4538/BMS-936558)" Result from Phase II Study in Patients with Melanoma Presented at European Cancer Congress 2013

Sep.27.2013……Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced

Sep.03.2013……Announcement on Annual Report 2013

Aug.27.2013……Rheumatoid Arthritis Drug@ORENCIA® SC 125mg Syringe 1mL Launched in Japan

Aug.13.2013……Ono Pharmaceutical and MSD applied for partial change in indications of "Sitagliptin", to add "type 2 diabetes"

Aug.06.2013……Application Submission for Approval for the Stability-Improved Formulation of Limaprost,an Oral Prostaglandin E1 Analogue in Japan

Aug.02.2013……Announcement on Financial Results for FY2013 1Q

Aug.02.2013……"Glactiv® tablets"for the oral treatment of type 2 diabetes Contraindication was removed and replaced by careful administration in patients with severe renal insufficiency

July.05.2013……Subcutaneous (SC) formulation of ORENCIA® (abatacept) Results of Year Two Data from AMPLE Study in Patients with Moderate to Severe Rheumatoid Arthritis Presented at the European League Against Rheumatism (EULAR) Annual Congress

Jun.28.2013……Rheumatoid Arthritis Drug ORENCIA® SC 125mg Syringe 1mL@Approved for Production and Distribution

Jun.26.2013……Notice of Resolutions Passed at the 65th Ordinary General Shareholders' Meeting

Jun.04.2013……Notice to Convene the 65th Ordinary General Shareholders' Meeting

Jun.04.2013……Bristol-Myers and Ono Pharmaceutical to Announce Lifting of Approval Conditions (Completion of PMS: "All-Case Surveillance") and Start of Co-Promotion

Jun.03.2013……Fully Human Anti-PD-1 Antibody "ONO-4538/BMS-936558" Results from Phase 1 Study in Patients with Melanoma Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO)

May.16.2013……Detailed Results of Phase III Trial of L-BLP25 in Patients with Non-Small Cell Lung Cancer (START) to be Presented at ASCO

May.13.2013……Voluntary adoption of International Financial Reporting Standards (IFRS)

May.13.2013……Partial Amendment of Articles of Incorporation

May.13.2013……Announcement on Financial Results for FY2012

May.09.2013……Announcement on Candidates of Members of the Board of Directors,Corporate Auditors and Corporate Officers

May.08.2013……Ono and Dainippon Sumitomo reach agreement on expanding business relating to Limaprost into China

Apr.18.2013……Ono Enters into License Agreement with Bial

Feb.20.2013……Additional Indication Application filed for Onoact® 50 for injection,Short-Acting Selective β1 Blocker in Japan

Feb.04.2013……Announcement on Financial Results for FY2012 3Q

Jan.25.2013……Discontinuation of Development for the Additional Indication of Carpal-Tunnel Syndrome, for Limaprost, an Oral Prostaglandin E1 Analogue

Dec.19.2012……Phase III Trial of L-BLP25 (Stimuvax®) in Patients with Non-Small Cell Lung Cancer Did not Meet Primary Endpoint

Nov.05.2012……Announcement on Financial Results for FY2012 2Q

Oct.23.2012……Ono Enters into Collaboration Agreement with Domain Therapeutics in the Field of GPCR-Based Drug Discovery

Oct.04.2012……Ono Conducts the Nation's First Microdosing Study Using Its Novel and Innovative Drug Candidate

Sep.28.2012……Announcement on Annual Report 2012

Sep.03.2012……Ono and Galapagos Subsidiary BioFocus Sign Drug Discovery Agreement in the Field of CNS Disorders

Aug.02.2012……Announcement on Financial Results for FY2012 1Q

Jul.23.2012……Carfilzomib, a proteasome inhibitor, has been granted FDA accelerated approval

Jul.10.2012……Bristol-Myers K.K. Files for Regulatory Approval in Japan for ORENCIA® Subcutaneous Injection (abatacept [rDNA]), Rheumatoid Arthritis Agent

Jul.02.2012……Clinical Trial Application submitted for Phase I study of ONO-7268MX1, peptide-cocktail vaccine for hepatocellular carcinoma

Jun.22.2012……Approval for Additional Indication of "EMEND® Capsule", an Antiemetic Selective Neurokinin-1 (NK1) Receptor Antagonist, for Pediatric Patients Aged 12 and older

Jun.21.2012……Voting result on Carfilzomib at FDA Oncologic Drug Advisory Committee

Jun.08.2012……Announcement on Appointment of Corporate Officer

Jun.04.2012……Fully Human Anti-PD-1 Antibody "ONO-4538/BMS-936558" Results from Phase 1 Study in Cancer Patients Published in New England Journal of Medicine (NEJM) and Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO)

May.30.2012……Ono and Galapagos Subsidiary BioFocus Sign an Additional Target Discovery Agreement in the Field of Allergic Disease

May.15.2012……Ono Enters into Drug Discovery Collaboraition with Scil Proteins for Affilin® Therapeutics

May.14.2012……Results of Phase‡UStudy of ONO-2745/CNS 7056, a Short-acting@General Anesthetic

May.9.2012……Announcement on Financial Results for FY2011

Apr.23.2012……Revisions of Consoldated Financial Forecasts

Apr.17.2012……ONO-4641 Met Primary Endpoint of Phase II Study in Multiple Sclerosis Patients

Dec.22.2011……Leukotriene Receptor Antagonist "Onon® Dry Syrup 10%" has received approval for the additional indication of allergic rhinitis

Dec.13.2011……Ono Enters into Drug Discovery Collaboration with Receptos on GPCR Protein Crystal Structure Determination Technology

Dec.08.2011……Launch of an Intravenous Antiemetic Selective Neurokinin-1iNK1jReceptor AntagonistC"PROEMEND® Intravenous infusion 150mg"

Nov.30.2011……FDA Acceptance of New Drug Application for Carfilzomib in Relapsed and Refractory Multiple Myeloma in the U.S.

Nov.14.2011……Announcement of the results from a Phase 2 study of "ONO-5163/KAI-4169"Fa calcium sensing receptor agonist

Oct.20.2011……Revisions of Consolidated Financial Forecasts

Oct.04.2011……Ono to Enter into License Agreements with Merck KGaA

Sep.29.2011……Additional Indication Application Filed for a Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting"EMEND® Capsule"for Pediatric Patients Aged 12 and older

Sep.29.2011……New Drug Application for Carfilzomib in Relapsed and Refractory Multiple Myeloma in the U.‚r.

Sep.26.2011……Approval received for an Intravenous Antiemetic Selective Neurokinin-1iNK1jReceptor AntagonistC"PROEMEND® Intravenous infusion 150mg"

Sep.21.2011……Ono and Bristol-Myers Squibb Enter into Strategic Agreement for Anti-PD-1 AntibodyCONO-4538^BMS-936558Cand ORENCIA®iabataceptjCRheumatoid Arthritis Agent

Sep.16.2011……Glactiv® has received approval for the additional indication of combination use with insulin

Sep.15.2011……Ono Enters License Agreement with KAI PhamaceuticalsCIncDfor KAI 4169

Sep.15.2011……Launch of RECARBON® Tablets 50mg/Bonoteo® Tablet 50mgCOnce per 4week Oral Osteoposis Treatment in Japan

Sep.14.2011……Ono Enters into License Agreement with Servier for Ivabradine

Sep.14.2011……Launch of Corebeta® for Injection 12.5mg for Improvement of Image Quality in Coronary CT Angiography in Japan

Aug.24.2011……Helsinn Announced to have Initiated Global Pivotal Phase III Clinical Program to Evaluate Anamorelin (ONO-7643/RC-1291) in Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia

Jul.19.2011……Launch of Rivastach® PatchCfor the Treatment of Dementia of Alzheimer's Type

Jul.01.2011……Approval for RECARBON® Tablets 50mg/Bonoteo® Tablet 50mg, Once per 4weeks Oral Osteoposis treatment in Japan

Jul.01.2011……Approval for Corebeta® for Injection 12.5mg for Improvement of Image Quality in Coronary CT Angiography in Japan

Jun.27.2011……Lead Compounds Were Successfully Identified in Ion Channel Drug Discovery Collaboration with Evotec

Jun.01.2011……Announcement on Co-development and Co-marketing Agreement for Carpal-tunnel Syndrome, an Additional Indication of Limaprost, an Oral Prostaglandin E1 Analogue

May.23.2011……Approval for Additional Indication Application of Type-2 Diabetes Drug,Glactiv Tablets
-Combination Therapy with Alpha-glucosidase Inhibitors-

May.11.2011……Announcement on Financial Results for FY2010

May.11.2011……Announcement on Introduct of Corporate Officer SystemCChanges of Members of the Board of Directors and Appointment of Corporate Officers

Apr.22,2011……Approval Received for Rivastach® Patch, for the treatment of Alzheimer's disease

Apr.06,2011……Announcement on Cancellation of the Company's Own Shares

Apr.05,2011……Launch of Orally Disintegrating Tablet of Staybla Tablets 0.1mg, a Drug for Overactive Bladder

Mar.29,2011……Ono Enters into License Agreement with OncoTherapy for New Therapeutic Cancer Peptide Vaccines

Mar.25,2011……Announcement on Results and Completion of Acquisition of the Company's Own Shares

Jan.11,2011……Ono and Galapagos subsidiary BioFocus sign target discovery agreement in the field of autoimmune disease

Dec.10,2010……Results of Phase Ⅱb Study of Carfizomib were Presented at the 52nd American Society of Hematology Annual Meeting

Nov.11,2010……Approval Received for Orally Disintegrating Tablet of imidafenacin (INN), a Drug for Overactive Bladder

Nov.04,2010……Announcement on Acquisition of the Company's Own Shares

Oct.28,2010……Ono and MSD Submit Additional Indication Application for Sitagliptin Combination Therapy with Insulin

To our investors
Alliances